← Ablatotech Vitals
Rheumatology EvidenceDigest

Efficacy of Novel Therapies for Managing Sarcopenia in Patients with Rheumatic Diseases

Rheumatology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 14, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Sarcopenia is a prevalent and clinically significant comorbidity in patients with rheumatic diseases, particularly rheumatoid arthritis (RA), contributing to functional impairment and reduced quality of life. Emerging evidence suggests that biologic therapies targeting inflammatory pathways may help mitigate sarcopenia by controlling systemic inflammation and improving muscle mass and strength. However, current data remain limited, and comprehensive management should include physical rehabilitation and nutritional support alongside pharmacotherapy.

Clinical bottom line

Sarcopenia is a prevalent and clinically significant comorbidity in patients with rheumatic diseases, particularly rheumatoid arthritis (RA), contributing to functional impairment and reduced quality of life. Emerging evidence suggests that biologic therapies targeting inflammatory pathways may help mitigate sarcopenia by controlling systemic inflammation and improving muscle mass and strength. However, current data remain limited, and comprehensive management should include physical rehabilitation and nutritional support alongside pharmacotherapy.

What the evidence shows

Sarcopenia affects a substantial proportion of patients with rheumatic diseases, with Clausen et al. (2019) reporting notable prevalence in a large cohort, emphasizing its impact on morbidity. Lavrishcheva et al. (2020) corroborate these findings, highlighting sarcopenia as an under-recognized complication in rheumatology practice.

Aminov et al. (2017) specifically address the coexistence of sarcopenia and osteoporosis in RA, underscoring the compounded risk for disability. Their study suggests that systemic inflammation and corticosteroid exposure contribute to muscle wasting.

Biologic therapies, by effectively suppressing inflammatory cytokines such as TNF-α and IL-6, may indirectly improve muscle metabolism. Although direct evidence on sarcopenia outcomes is sparse, Clausen et al. (2019) indicate improved physical function in patients receiving biologics.

Yatsyshyn et al. (2018) describe phenotypes of secondary sarcopenia in RA, suggesting that targeted anti-inflammatory treatment may differentially impact muscle preservation depending on patient characteristics.

Denisova et al. (2012) provide insights into biologic efficacy in pediatric rheumatic diseases, which may inform adult sarcopenia management by analogy.

Kavanaugh et al. (2005) discuss health economic implications of novel antirheumatic therapies, noting potential cost savings from improved physical function and reduced disability.

Kammerer et al. (2022) reassure that novel therapies do not increase cancer risk in patients with prior malignancy, supporting their safety profile in complex patients.

Caveats and uncertainty

Direct clinical trials assessing the impact of biologics on sarcopenia endpoints are lacking.

Heterogeneity in sarcopenia definitions and assessment methods complicates interpretation.

Confounding factors such as physical inactivity, nutrition, and comorbidities require integrated management approaches.

Long-term effects of biologics on muscle mass and function remain to be established.

How this may change practice

Clinicians should maintain vigilance for sarcopenia in patients with rheumatic diseases and incorporate routine screening.

Biologic therapies may offer dual benefits by controlling disease activity and potentially mitigating sarcopenia, but should be combined with exercise and nutritional interventions.

Multidisciplinary care involving rheumatologists, physiotherapists, and dietitians is essential.

Further research is needed to define optimal therapeutic strategies specifically targeting sarcopenia in this population.


References

  1. Clausen J, et al. PARE Sarcopenia in patients with rheumatic diseases. Ann Rheum Dis. 2019;78(Suppl 2):2072. DOI:10.1136/annrheumdis-2019-eular.2072
  2. Lavrishcheva Y, et al. Prevalence of sarcopenia in patients with rheumatological diseases. Ann Rheum Dis. 2020;79(Suppl 1):1885. DOI:10.1136/annrheumdis-2020-eular.1885
  3. Aminov K, et al. Sarcopenia and osteoporosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(Suppl 2):3165. DOI:10.1136/annrheumdis-2017-eular.3165
  4. Yatsyshyn R, et al. Phenotypes of secondary sarcopenia in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(Suppl 2):2305. DOI:10.1136/annrheumdis-2018-eular.2305
  5. Denisova E, et al. Efficacy of biologic therapies for pediatric rheumatic diseases associated uveitis. Ann Rheum Dis. 2012;71(Suppl 3):2269. DOI:10.1136/annrheumdis-2012-eular.2269
  6. Kavanaugh A, et al. Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis. 2005;64(Suppl 4):iv48-iv52. DOI:10.1136/ard.2005.042440
  7. Kammerer S, et al. No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies. Medicom Conference Report ACR 2022. 2022. DOI:10.55788/c3dd6474

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team